Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chese-Pond's

This article was originally published in The Tan Sheet

Executive Summary

Vaseline Petroleum Jelly Cream scheduled for October launch. The $ 2 mil. ad/promotional budget for the line extension includes introductory FSI containing a free trial size or $ 1 off a full size product, direct mail 75 cent coupons and samples, a $ 1.50 rebate with one proof of purchase, and free trial size products on 7.5 ounce packages of Vaseline Petroleum Jelly. Comprised of 30% Vaseline Petroleum Jelly, other emollients and vitamin E, the cream will be available in a 4.5 ounce jar or tube carrying a suggested retail price of $ 2.69. a 2 oz. tube is priced at $ 1.79 and a .85 ounce trial size at 99 cents. Chese-Pond's also is launching Vaseline Lip Therapy in October, supported with a $ 5 mil. print ad campaign. "Advanced" and "cherry" Lip Therapy formulas contain an SPF 15 sunscreen while the "medicated" formula includes camphor, allantoin, menthol and phenol.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel